Dosages of melphalan / cytarabine:
The median dosage of melphalan was 1x40 mg/m² with a range of 1x20 mg/m²
to 2x60 mg/m². The reason for the low dosage of melphalan in one case
was a high cumulative toxicity prior to the melphalan / cytarabine
therapy. A very aggressive form of AML was the reason for choosing a
higher dosage of melphalan. The median dosage of cytarabine was 3 x 1
g/m² with a range of 5 x 100 mg/m² to 4 x 1 g/m². The reason for
adopting a low dosage of cytarabine was high cumulative toxicity prior
to the melphalan / cytarabine therapy. In this case cytarabine was given
as a continuous infusion. Four patients received additional intrathecal
chemotherapy. One patient received additional daratumomab. In this case
the underlying disease was a CD38-positive T-lymphoblastic lymphoma. One
patient with a common ALL received additional blinatumomab and one
patient with AML received additional venetoclax. For further information
concerning the melphalan / cytarabine regimen see Table 2.